Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of sitagliptin in pediatric type 2 diabetes mellitus with inadequate glycemic control
2011-002528-42Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sitagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline in hemoglobin A1c. Started Sep 2011; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-002528-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002528-42.